Find Ifosfamide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

REF. STANDARDS OR IMPURITIES

0

USP

0

JP

FDF DossiersDRUG PRODUCT COMPOSITIONS

7RELATED EXCIPIENT COMPANIES

8EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Isophosphamide, 3778-73-2, Iphosphamide, Isofosfamide, Ifex, Ifosfamid
Molecular Formula
C7H15Cl2N2O2P
Molecular Weight
261.08  g/mol
InChI Key
HOMGKSMUEGBAAB-UHFFFAOYSA-N
FDA UNII
UM20QQM95Y

Ifosfamide
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
Ifosfamide is an Alkylating Drug. The mechanism of action of ifosfamide is as an Alkylating Activity.
1 2D Structure

Ifosfamide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N,3-bis(2-chloroethyl)-2-oxo-1,3,25-oxazaphosphinan-2-amine
2.1.2 InChI
InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
2.1.3 InChI Key
HOMGKSMUEGBAAB-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CN(P(=O)(OC1)NCCCl)CCCl
2.2 Other Identifiers
2.2.1 UNII
UM20QQM95Y
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Asta Z 4942

2. Holoxan

3. Iphosphamide

4. Iso Endoxan

5. Iso-endoxan

6. Isofosfamide

7. Isophosphamide

8. Nsc 109,724

9. Nsc 109724

10. Nsc-109,724

11. Nsc-109724

12. Nsc109,724

13. Nsc109724

2.3.2 Depositor-Supplied Synonyms

1. Isophosphamide

2. 3778-73-2

3. Iphosphamide

4. Isofosfamide

5. Ifex

6. Ifosfamid

7. Mitoxana

8. Iphosphamid

9. Isoendoxan

10. Naxamide

11. I-phosphamide

12. Holoxan

13. Cyfos

14. Ifsofamide

15. Holoxan 1000

16. Asta Z 4942

17. Mjf 9325

18. Ifosfamida

19. Ifosfamidum

20. Mjf-9325

21. Isosfamide

22. Nsc-109724

23. Nci-c01638

24. Z4942

25. Z-4942

26. Ifomide

27. Nsc 109724

28. A 4942

29. Z 4942

30. 2h-1,3,2-oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide

31. 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorine 2-oxide

32. Nsc109724

33. N,3-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

34. N-(2-chloroethyl)-n'-(2-chloroethyl)-n',o-propylenephosphoric Acid Diamide

35. Um20qqm95y

36. N,3-bis(2-chloroethyl)tetrahydro-2h-1,3,2-oxazaphosphorin-2-amine 2-oxide

37. 3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide

38. Chebi:5864

39. Ifosphamide

40. 1,3,2-oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

41. 2h-1,3,2-oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

42. 3-(2-chloroethyl)-2-(2-chloroethylamino)tetrahydro-2h-1,3,2-oxaazaphosphorin 2-oxide

43. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2h-1,3,2-oxazaphosphorineoxide

44. N-(2-chloroethyl)-n'-(2-chloroethyl)-n',o-propylene Phosphoric Acid Ester Diamide

45. Ncgc00016639-01

46. Cas-3778-73-2

47. Dsstox_cid_760

48. Ifosfamide Sterile

49. Dsstox_rid_75775

50. Dsstox_gsid_20760

51. Ifosfamidum [inn-latin]

52. Ifosfamida [inn-spanish]

53. (r)-ifosfamide

54. (s)-ifosfamide

55. (r)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide

56. Ccris 352

57. Hsdb 7023

58. Sr-05000002022

59. Einecs 223-237-3

60. Ifex (tn)

61. Unii-um20qqm95y

62. Brn 0611835

63. Ifosfamide (jan/usp/inn)

64. N,3-bis(2-chloroethyl)-2-oxo-1,3,2?^{5}-oxazaphosphinan-2-amine

65. Ifosfamid A

66. 3-(2-chloroethyl)-2-((2-chloroethyl)amino)perhydro-2h-1,3,2-oxazaphosphorineoxide

67. Ifosfamide In Bulk

68. 2,3-(n,n(sup 1)-bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd

69. Isophosphamide,(s)

70. N,n-bis(beta-chloroethyl)-amino-n',o-propylene-phosphoric Acid Ester Diamide

71. N-(2-chloroethyl)-n'-(2-chloroethyl)-n',o-propylenephosphoric Acid Ester Diamide

72. Mfcd00057374

73. 3-(2-chloroethyl)-2-((2-chloroethyl)amino)perhydro-2h-1,3,2-oxazaphosphorine Oxide

74. N-(2-chloraethyl)-n'-(2-chloraethyl)-n',o-propylen-phosphorsaureester-diamid [german]

75. Ifosfamide - Bio-x

76. Ifosfamide [usan:usp:inn:ban:jan]

77. Starbld0001221

78. Ifosfamide, >=98%

79. Ifosfamide [mi]

80. Isocyclophosphamide

81. Ifosfamide [inn]

82. Ifosfamide [jan]

83. Prestwick0_000833

84. Prestwick1_000833

85. Prestwick2_000833

86. Prestwick3_000833

87. Ifosfamide [hsdb]

88. Ifosfamide [usan]

89. Intermediate Of Ifosfamide

90. Ifosfamide [vandf]

91. N-(2-chloraethyl)-n'-(2-chloraethyl)-n',o-propylen-phosphorsaureester-diamid

92. Ifosfamide [mart.]

93. Schembl4885

94. Chembl1024

95. Ifosfamide [usp-rs]

96. Ifosfamide [who-dd]

97. Bspbio_000785

98. Isophosphamide [iarc]

99. Mls002154021

100. Ifex (tn) (bristol Meyers)

101. Spbio_002706

102. Bpbio1_000865

103. Gtpl7201

104. Dtxsid7020760

105. Ifosfamide [ep Impurity]

106. Ifosfamide [orange Book]

107. Ifosfamide [ep Monograph]

108. (s)-3-(2-chloroethyl)-2-((2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide

109. Bdbm189358

110. Hms1570h07

111. Hms2090m12

112. Hms2093n07

113. Hms2097h07

114. Hms2232o10

115. Hms3374b08

116. Hms3654b15

117. Hms3714h07

118. Ifosfamide [usp Monograph]

119. Pharmakon1600-01505480

120. {3-(2-chloroethyl)-2-[(2-

121. Bcp06596

122. Wln: T6npotj Am2g Bo B2g

123. Tox21_110539

124. Tox21_201815

125. Tox21_302775

126. Bbl028071

127. N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine

128. N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine

129. Nsc759154

130. S1302

131. Stl058690

132. Akos005711213

133. N,3-bis(2-chloroethyl)tetrahydro-2h-1,3,2-oxazaphosphorin-2-amine-2-oxide

134. Tox21_110539_1

135. Ab02316

136. Ac-2113

137. Ccg-213464

138. Cs-1424

139. Db01181

140. Nsc-759154

141. N-(2-chloroethyl)-n-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine

142. Ifosfamide, Analytical Reference Material

143. Ncgc00179435-01

144. Ncgc00179435-02

145. Ncgc00179435-03

146. Ncgc00179435-06

147. Ncgc00179435-07

148. Ncgc00256413-01

149. Ncgc00259364-01

150. As-10978

151. Bi166243

152. Hy-17419

153. Nci60_000233

154. Smr001233348

155. Sbi-0206804.p001

156. Db-049196

157. Ab00513932

158. Ft-0603650

159. Ft-0670282

160. I0713

161. Sw197177-4

162. C07047

163. D00343

164. Ab00513932-06

165. Ab00513932-07

166. Ab00513932-08

167. Ab00513932_09

168. Ab00513932_10

169. 778i732

170. A823873

171. Q418560

172. Q-101874

173. Sr-05000002022-1

174. Sr-05000002022-3

175. Sr-05000002022-5

176. Brd-a67097164-001-11-2

177. Ifosfamide, British Pharmacopoeia (bp) Reference Standard

178. Ifosfamide, European Pharmacopoeia (ep) Reference Standard

179. Ifosfamide, United States Pharmacopeia (usp) Reference Standard

180. 2,n(sup 1)-bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxy-

181. 2,n(sup 1)-bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd

182. N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l;{5}-oxazaphosphinan-2-amine

183. {3-(2-chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2h-1,3,} 2-oxazaphosphorine Oxide

184. 1,2-oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

185. 2h-1,2-oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide

186. 2h-1,2-oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

187. 3-(2-chloroethyl)-2-(2-chloroethylamino)tetrahydro-2h-1,3,2-oxazaphosphorin-2-one

188. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2$l^{5}-oxazaphosphinan-2-one

189. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2lambda5-oxazaphosphinan-2-one

190. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2h-1,2-oxazaphosphorine Oxide

191. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2h-1,2-oxazaphosphorineoxide

192. 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2h-1,2-oxazaphosphorine 2-oxide

193. N,3-bis(2-chloroethyl)tetrahydro-2h-1,3,2-oxazaphosphinan-2-amine 2-oxide #

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 261.08 g/mol
Molecular Formula C7H15Cl2N2O2P
XLogP30.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count5
Exact Mass260.0248201 g/mol
Monoisotopic Mass260.0248201 g/mol
Topological Polar Surface Area41.6 Ų
Heavy Atom Count14
Formal Charge0
Complexity218
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameIfex
PubMed HealthIfosfamide (Injection)
Drug ClassesAntineoplastic Agent
Drug LabelIFEX (ifosfamide for injection, USP) single-dose vials for constitution and administration by intravenous infusion each contain 1 gram or 3 grams of sterile ifosfamide. Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustard...
Active IngredientIfosfamide
Dosage FormInjectable
RouteInjection
Strength1gm/vial; 3gm/vial
Market StatusPrescription
CompanyBaxter Hlthcare

2 of 4  
Drug NameIfosfamide
PubMed HealthIfosfamide (Injection)
Drug ClassesAntineoplastic Agent
Drug LabelIfosfamide injection sterile, single-dose vials for administration by intravenous infusion each contains 1 gram or 3 grams of ifosfamide, USP. The 1-gram vial also contains 69.0 mg monobasic sodium phosphate monohydrate, USP, 21.3 mg dibasic sodium p...
Active IngredientIfosfamide
Dosage FormInjectable
RouteInjection
Strength1gm/20ml (50mg/ml); 3gm/60ml(50mg/ml); 1gm/vial; 3gm/vial; 1gm/20ml(50mg/ml); 3gm/60ml (50mg/ml)
Market StatusPrescription
CompanyTeva Pharms Usa; Fresenius Kabi Usa; Onco Therapies; Eurohlth Intl

3 of 4  
Drug NameIfex
PubMed HealthIfosfamide (Injection)
Drug ClassesAntineoplastic Agent
Drug LabelIFEX (ifosfamide for injection, USP) single-dose vials for constitution and administration by intravenous infusion each contain 1 gram or 3 grams of sterile ifosfamide. Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustard...
Active IngredientIfosfamide
Dosage FormInjectable
RouteInjection
Strength1gm/vial; 3gm/vial
Market StatusPrescription
CompanyBaxter Hlthcare

4 of 4  
Drug NameIfosfamide
PubMed HealthIfosfamide (Injection)
Drug ClassesAntineoplastic Agent
Drug LabelIfosfamide injection sterile, single-dose vials for administration by intravenous infusion each contains 1 gram or 3 grams of ifosfamide, USP. The 1-gram vial also contains 69.0 mg monobasic sodium phosphate monohydrate, USP, 21.3 mg dibasic sodium p...
Active IngredientIfosfamide
Dosage FormInjectable
RouteInjection
Strength1gm/20ml (50mg/ml); 3gm/60ml(50mg/ml); 1gm/vial; 3gm/vial; 1gm/20ml(50mg/ml); 3gm/60ml (50mg/ml)
Market StatusPrescription
CompanyTeva Pharms Usa; Fresenius Kabi Usa; Onco Therapies; Eurohlth Intl

4.2 Therapeutic Uses

Ifosfamide currently is approved for use in combination with other drugs for germ cell testicular cancer & is widely used to treat pediatric & adult sarcomas. Clinical trials also have shown ifosfamide to be active against carcinomas of the cervix & lung & against lymphomas. It is a common component of high-dose chemotherapy regimens with bone marrow or stem cell rescue; in these regimens, in total doses of 12-14 g/sq m, it may cause severe neurological toxicity, including coma & death. This toxicity is thought to result form a metabolite, chloracetaldehyde. In addition to hemorrhagic cystitis, ifosfamide causes nausea, vomiting, anorexia, leukopenia, nephrotoxicity, & CNS disturbances (especially somnolence & confusion).

Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1396


Ifosfamide is indicated, in combination with other antineoplastic agents and a prophylactic agent against hemorrhagic cystitis (such as mesna), for treatment of germ cell testicular tumors. /Included in US product labeling/

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1677


Ifosfamide is indicated as reasonable medical therapy for treatment of head and neck carcinoma. (Evidence rating: IIID) /NOT included in US product labeling/

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1677


Ifosfamide is used for treatment of soft-tissue sarcomas, Ewing's sarcoma, and Hodgkin's and non-Hodgkin's lymphomas. /NOT included in US product labeling/

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1677


For more Therapeutic Uses (Complete) data for IFOSFAMIDE (9 total), please visit the HSDB record page.


4.3 Drug Warning

It is a common component of high-dose chemotherapy regimens with bone marrow or stem cell rescue; in these regimens, in total doses of 12-14 g/sq m, it may cause severe neurological toxicity, including coma & death. This toxicity is thought to result form a metabolite, chloracetaldehyde. In addition to hemorrhagic cystitis, ifosfamide causes nausea, vomiting, anorexia, leukopenia, nephrotoxicity, & CNS disturbances (especially somnolence & confusion).

Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1396


Ifosfamide is distributed into breast milk. Breast feeding is not recommended during chemotherapy because of the risks to the infant (adverse effects, mutagenicity, carcinogenicity).

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1677


The bone marrow depressant effects of ifosfamide may result in an increased incidence of microbial infection, delayed healing, and gingival bleeding. Dental work, whenever possible, should be completed prior to initiation of therapy or deferred until blood counts have returned to normal. Patients should be instructed in proper oral hygiene during treatment, including caution in use of regular toothbrushes, dental floss, and toothpicks.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1677


Many side effects of antineoplastic therapy are unavoidable and represent the medication's pharmacologic action. Some of these (for example, leukopenia and thrombocytopenia) are actually used as parameters to aid in individual dosage titration.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 1678


For more Drug Warnings (Complete) data for IFOSFAMIDE (20 total), please visit the HSDB record page.


4.4 Drug Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Ifosfamide requires activation by microsomal liver enzymes to active metabolites in order to exert its cytotoxic effects. Activation occurs by hydroxylation at the ring carbon atom 4 to form the unstable intermediate 4-hydroxyifosfamide. This metabolite than rapidly degrades to the stable urinary metabolite 4-ketoifosfamide. The stable urinary metabolite, 4-carboxyifosfamide, is formed upon opening of the ring. These urinary metabolites have not been found to be cytotoxic. N, N-bis (2-chloroethyl)-phosphoric acid diamide (ifosphoramide) and acrolein are also found. The major urinary metabolites, dechloroethyl ifosfamide and dechloroethyl cyclophosphamide, are formed upon enzymatic oxidation of the chloroethyl side chains and subsequent dealkylation. It is the alkylated metabolites of ifosfamide that have been shown to interact with DNA. Ifosfamide is cycle-phase nonspecific.


5.2 MeSH Pharmacological Classification

Antineoplastic Agents, Alkylating

A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
IFOSFAMIDE
5.3.2 FDA UNII
UM20QQM95Y
5.3.3 Pharmacological Classes
Alkylating Drug [EPC]; Alkylating Activity [MoA]
5.4 ATC Code

L01AA06

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01A - Alkylating agents

L01AA - Nitrogen mustard analogues

L01AA06 - Ifosfamide


5.5 Absorption, Distribution and Excretion

Route of Elimination

Ifosfamide is extensively metabolized in humans and the metabolic pathways appear to be saturated at high doses. After administration of doses of 5 g/m2 of 14C-labeled ifosfamide, from 70% to 86% of the dosed radioactivity was recovered in the urine, with about 61% of the dose excreted as parent compound. At doses of 1.62.4 g/m2 only 12% to 18% of the dose was excreted in the urine as unchanged drug within 72 hours.


Volume of Distribution

Ifosfamide volume of distribution (Vd) approximates the total body water volume, suggesting that distribution takes place with minimal tissue binding. Following intravenous administration of 1.5 g/m2 over 0.5 hour once daily for 5 days to 15 patients with neoplastic disease, the median Vd of ifosfamide was 0.64 L/kg on Day 1 and 0.72 L/kg on Day 5. When given to pediatric patients, the volume of distribution was 211.6 L/m^2.


Clearance

2.40.33 L/h/m^2 [pediatric patients]


Renal excretion & t1/2 are dose & schedule dependent. 60-80% recovered as unchanged drug or metabolite in urine within 72 hr after admin.

Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 90-13


The distribution of ifosfamide (IF) and its metabolites 2-dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE), 4-hydroxyifosfamide (4OHIF) and ifosforamide mustard (IFM) between plasma and erythrocytes was examined in vitro and in vivo. In vitro distribution was investigated by incubating blood with various concentrations of IF and its metabolites. In vivo distribution of IF, 2DCE, 3DCE and 4OHIF was determined in 7 patients receiving 9 g/m(2)/72 h intravenous continuous IF infusion. In vitro distribution equilibrium between erythrocytes and plasma was obtained quickly after drug addition. Mean (+/-sem) in vitro and in vivo erythrocyte (e)-plasma (p) partition coefficients (P(e/p)) were 0.75+/-0.01 and 0.81+/-0.03, 0.62+/-0.09 and 0.73+/-0.05, 0.76+/-0.10 and 0.93+/-0.05 and 1.38+/-0.04 and 0.98+/-0.09 for IF, 2DCE, 3DCE and 4OHIF, respectively. These ratios were independent of concentration and unaltered with time. The ratios of the area under the erythrocyte and plasma concentration--time curves (AUC(e/p)) were 0.96+/-0.03, 0.87+/-0.07, 0.98+/-0.06 and 1.34+/-0.39, respectively. A time- and concentration-dependent distribution--equilibrium phenomenon was observed with the relative hydrophilic IFM. It is concluded that IF and metabolites rapidly reach distribution equilibrium between erythrocytes and plasma; the process is slower for IFM. Drug distribution to the erythrocyte fraction ranged from about 38% for 2DCE to 58% for 4OHIF, and was stable over a wide range of clinically relevant concentrations. A strong parallelism in the erythrocyte and plasma concentration profiles was observed for all compounds. Thus, pharmacokinetic assessment using only plasma sampling yields direct and accurate insights into the whole blood kinetics of IF and metabolites and may be used for pharmacokinetic-pharmacodynamic studies.

PMID:11745912 Kerbusch T, et al; Biopharm Drug Dispos 22 (3): 99-108 (2001)


... To assess the feasibility of a sparse sampling approach for the determination of the population pharmacokinetics of ifosfamide, 2- and 3-dechloroethyl-ifosfamide and 4-hydroxy-ifosfamide in children treated with single-agent ifosfamide against various malignant tumours. ... Pharmacokinetic assessment followed by model fitting. Patients: The analysis included 32 patients aged between 1 and 18 years receiving a total of 45 courses of ifosfamide 1.2, 2 or 3 g/m2 in 1 or 3 hours on 1, 2 or 3 days. ... A total of 133 blood samples (median of 3 per patient) were collected. Plasma concentrations of ifosfamide and its dechloroethylated metabolites were determined by gas chromatography. Plasma concentrations of 4-hydroxy-ifosfamide were measured by high-performance liquid chromatography. The models were fitted to the data using a nonlinear mixed effects model as implemented in the NONMEM program. A cross-validation was performed. ... Population values (mean +/- standard error) for the initial clearance and volume of distribution of ifosfamide were estimated at 2.36 +/- 0.33 L/h/m2 and 20.6 +/- 1.6 L/m2 with an interindividual variability of 43 and 32%, respectively. The enzyme induction constant was estimated at 0.0493 +/- 0.0104 L/h2/m2. The ratio of the fraction of ifosfamide metabolised to each metabolite to the volume of distribution of that metabolite, and the elimination rate constant, of 2- and 3-dechloroethyl-ifosfamide and 4-hydroxy-ifosfamide were 0.0976 +/- 0.0556, 0.0328 +/- 0.0102 and 0.0230 +/- 0.0083 m2/L and 3.64 +/- 2.04, 0.445 +/- 0.174 and 7.67 +/- 2.87 h(-1), respectively. Interindividual variability of the first parameter was 23, 34 and 53%, respectively. Cross-validation indicated no bias and minor imprecision (12.5 +/- 5.1%) for 4-hydroxy-ifosfamide only. ... We have developed and validated a model to estimate ifosfamide and metabolite concentrations in a paediatric population by using sparse sampling.

PMID:11523727 Kerbusch T, et al; Clin Pharmacokinet 40 (8): 615-625 (2001)


... The population pharmacokinetics and pharmacodynamics of the cytostatic agent ifosfamide and its main metabolites 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were assessed in patients with soft tissue sarcoma. ... Twenty patients received 9 or 12 g/m2 ifosfamide administered as a 72-h continuous intravenous infusion. The population pharmacokinetic model was built in a sequential manner, starting with a covariate-free model and progressing to a covariate model with the aid of generalised additive modelling. ... The addition of the covariates weight, body surface area, albumin, serum creatinine, serum urea, alkaline phosphatase and lactate dehydrogenase improved the prediction errors of the model. Typical pretreatment (mean +/- SEM) initial clearance of ifosfamide was 3.03 +/- 0.18 l/h with a volume of distribution of 44.0 +/- 1.8 l. Autoinduction, dependent on ifosfamide levels, was characterised by an induction half-life of 11.5 +/- 1.0 h with 50% maximum induction at 33.0 +/- 3.6 microM ifosfamide. Significant pharmacokinetic-pharmacodynamic relationships (P = 0.019) were observed between the exposure to 2- and 3-dechloroethylifosfamide and orientational disorder, a neurotoxic side-effect. No pharmacokinetic-pharmacodynamic relationships between exposure to 4-hydroxyifosfamide and haematological toxicities could be observed in this population.

PMID:11699611 Kerbusch T, et al; Eur J Clin Pharmacol 57 (6-7): 467-477 (2001)


For more Absorption, Distribution and Excretion (Complete) data for IFOSFAMIDE (6 total), please visit the HSDB record page.


5.6 Metabolism/Metabolites

Primarily hepatic. Ifosfamide is metabolized through two metabolic pathways: ring oxidation ("activation") to form the active metabolite, 4-hydroxy-ifosfamide and side-chain oxidation to form the inactive metabolites, 3-dechloro-ethylifosfamide or 2-dechloroethylifosfamide with liberation of the toxic metabolite, chloroacetaldehyde. Small quantities (nmol/mL) of ifosfamide mustard and 4-hydroxyifosfamide are detectable in human plasma. Metabolism of ifosfamide is required for the generation of the biologically active species and while metabolism is extensive, it is also quite variable among patients.


Like cyclophosphamide, ifosfamide is activated in the liver by hydroxylation. However, the activation of ifosfamide proceeds more slowly, with greater production of dechlorinated metabolites & chloroacetaldehyde. These differences in metabolism likely account for the higher doses of ifosfamide required for equitoxic effects & the possible difference in antitumor spectrum of the two agents.

Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1391


Like cyclophosphamide, isophosphamide requires metabolism by microsomal enzymes to act as a cytotoxic agent. It is rapidly metabolized in many species, including rodents and dogs; the urinary metabolites indicate that a series of reactions take place analogous to those in the metabolism of cyclophosphamide. Acrolein is produced during its oxidative degradation, and one product of the reaction is the ring-opened carboxy derivative. Dogs also rapidly metabolize isophosphamide, and the carboxy derivative and 4-keto isophosphamide have been identified in the urine.

IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V26 243 (1981)


The aim of this study was to develop a population pharmacokinetic model that could describe the pharmacokinetics of ifosfamide. 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide, and calculate their plasma exposure and urinary excretion. A group of 14 patients with small-cell lung cancer received a 1-h intravenous infusion of 2.0 or 3.0 g/m2 ifosfamide over 1 or 2 days in combination with 175 mg/m2 paclitaxel and carboplatin at AUC 6. The concentration-time profiles of ifosfamide were described by an ifosfamide concentration-dependent development of autoinduction of ifosfamide clearance. Metabolite compartments were linked to the ifosfamide compartment enabling description of the concentration-time profiles of 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide. The Bayesian estimates of the pharmacokinetic parameters were used to calculate the systemic exposure to ifosfamide and its metabolites for the four ifosfamide schedules. Fractionation of the dose over 2 days resulted increased metabolite formation, especially of 2-dechloroethylifosfamide, probably due to increased autoinduction. Renal recovery was only minor with 6.6% of the administered dose excreted unchanged and 9.8% as dechloroethylated metabolites. In conclusion, ifosfamide pharmacokinetics were described with an ifosfamide concentration-dependent development of autoinduction and allowed estimation of the population pharmacokinetics of the metabolites of ifosfamide. Fractionation of the dose resulted in increased exposure to 2-dechloroethylifosfamide, probably due to increased autoinduction.

PMID:11488525 Kerbusch T, et al; Cancer Chemother Pharmacol 48 (1): 53-61 (2001)


The anticancer drug ifosfamide is a prodrug requiring activation through 4-hydroxyifosfamide to ifosforamide mustard, to exert cytotoxicity. Deactivation of ifosfamide leads to 2- and 3-dechloroethylifosfamide and the release of potentially neurotoxic chloracetaldehyde. The aim of this study was to quantify and to compare the pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide, 4-hydroxyifosfamide, and ifosforamide mustard in short (1-4 h), medium (24-72 h), and long infusion durations (96-240 h) of ifosfamide. An integrated population pharmacokinetic model was used to describe the autoinducible pharmacokinetics of ifosfamide and its four metabolites in 56 patients. The rate by which autoinduction of the metabolism of ifosfamide developed was found to be significantly dependent on the infusion schedule. The rate was 52% lower with long infusion durations compared with short infusion durations. This difference was, however, comparable with its interindividual variability (22%) and was, therefore, considered to be of minor clinical importance. Autoinduction caused a less than proportional increase in the area under the ifosfamide plasma concentration-time curve (AUC) and more than proportional increase in metabolite exposure with increasing ifosfamide dose. During long infusion durations dose-corrected exposures (AUC/D) were significantly decreased for ifosfamide and increased for 3-dechloroethylifosfamide compared with short infusion durations. No differences in dose-normalized exposure to ifosfamide and metabolites were observed between short and medium infusion durations. This study demonstrates that the duration of ifosfamide infusion influences the exposure to the parent and its metabolite 3-dechloroethylifosfamide. The observed dose and infusion duration dependence should be taken into account when modeling ifosfamide metabolism.

PMID:11408362 Kerbusch T, et al; Drug Metab Dispos 29 (7): 967-975 (2001)


Ifosfamide is a known human metabolite of L-trofosfamide.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.7 Biological Half-Life

7-15 hours. The elimination half-life increase appeared to be related to the increase in ifosfamide volume of distribution with age.


The elimination half-life associated with doses of 2.5 g/sq m is 6-8 hr, whereas the elimination half-life associated with doses of 3.5-5 g/sq m is 14-16 hr.

Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 91-22


5.8 Mechanism of Action

The exact mechanism of ifosfamide has not been determined, but appears to be similar to other alkylating agents. Ifosfamide requires biotransformation in the liver by mixed-function oxidases (cytochrome P450 system) before it becomes active. After metabolic activation, active metabolites of ifosfamide alkylate or bind with many intracellular molecular structures, including nucleic acids. The cytotoxic action is primarily through the alkylation of DNA, done by attaching the N-7 position of guanine to its reactive electrophilic groups. The formation of inter and intra strand cross-links in the DNA results in cell death.


Mechanism of action: metabolites cause alkylation of DNA. /from table/

Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 90-12


Ifosfamide, a structural analog of cyclophosphamide, belongs to the oxazaphosphorine class of antitumor alkylating agents which must be activated by the mixed function oxidase system of the liver. The 4-hydroxy oxazaphosphorines are a reactive species capable of interacting with nucleic acids & cellular materials to cause cell damage & death. The 4-hydroxy metabolite spontaneously liberates acrolein in many sites throughout the body & it is this substance that is responsible for oxazaphosphorine urotoxicity. Both ifosfamide & cyclophosphamide produce cystitis characterized by tissue edema & ulceration followed by sloughing of mucosal epithelial cells, necrosis of smooth muscle fibers & arteries, & culminating in focal hemorrhage. The selective urotoxicity of oxazaphosphorine occurs because the bladder contains a very low concn of thiol cmpds (glutathione, cysteine) which, by virtue of their nucleophilic sulfhydryl groups, are able to react & neutralize many reactive chemicals. Because the metabolic activation of ifosfamide proceeds more slowly than that of cyclophosphamide, doses of ifosfamide are 3-4 times higher than those of cyclophosphamide. This explains the higher incidence of urotoxicity associated with ifosfamide.

Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 91-21


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 25081

Submission : 2009-07-20

Status : Active

Type : II

Aarti Industries Company Banner

02

German Wound Congress
Not Confirmed

02

German Wound Congress
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 3506

Submission : 1979-04-24

Status : Active

Type : II

blank

03

Ifotam Co Ltd

Poland

USDMF

arrow
German Wound Congress
Not Confirmed

03

Ifotam Co Ltd

Poland
arrow
German Wound Congress
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 15064

Submission : 2000-09-29

Status : Active

Type : II

blank

04

German Wound Congress
Not Confirmed

04

German Wound Congress
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-09-04

Pay. Date : 2015-08-18

DMF Number : 11290

Submission : 1995-01-11

Status : Active

Type : II

blank

05

Degussa Huls Ag

Country

USDMF

arrow
German Wound Congress
Not Confirmed

05

Degussa Huls Ag

Country
arrow
German Wound Congress
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 14796

Submission : 2000-03-28

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

read-more
read-moreread-more

01

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

Certificate Number : R1-CEP 2013-026 - Rev 00

Status : Withdrawn by Holder

Issue Date : 2019-09-04

Type : Chemical

Substance Number : 1529

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

Flag India
Digital Content Digital Content

Ifosfamide Ph. Eur/BP/USP

Date of Issue : 2025-08-22

Valid Till : 2028-08-21

Written Confirmation Number : WC-0099

Address of the Firm : Plot No.E-50, 50/1 and 59/1, Unit-IV, MIDC, Tarapur-401506, Taluka: Palghar, Dis...

Aarti Industries Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

Flag India
Digital Content Digital Content

IFOSFAMIDE

NDC Package Code : 15308-0411

Start Marketing Date : 1990-01-01

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Aarti Industries Company Banner

02

German Wound Congress
Not Confirmed
arrow
arrow
German Wound Congress
Not Confirmed

IFOSFAMIDE

NDC Package Code : 57884-0006

Start Marketing Date : 2010-08-25

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Flag U.S.A
Digital Content Digital Content

Ifosfamide

About the Company : ChemWerth, established in 1982, is a US-headquartered full-service generic API company. It supplies cGMP-quality APIs to regulated markets worldwide, with exclusive partnerships fo...

ChemWerth, established in 1982, is a US-headquartered full-service generic API company. It supplies cGMP-quality APIs to regulated markets worldwide, with exclusive partnerships for product development, compliance, and secure logistics. ChemWerth accesses over 500 APIs and 30 manufacturing facilities across the US, Europe, India, and China, acts as a regulatory agent for 25+ FDA-approved facilities, sells 100+ products, and operates in 38 countries. In 2020, it filed its 500th DMF with the FDA . Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Chemwerth Compnay Banner

02

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Ifosfamide

About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...

LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product CDMO, offering formulation, analytical method development and testing, regulatory support, and commercial manufacturing. Supported by a network of over 220 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
LGM Pharma CB

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

Flag India
Digital Content Digital Content

Ifosfamide

About the Company : Aarti Pharmalabs is generic APIs & Intermediates manufacturing company & small molecule drug substance CDMO and the largest Indian manufacturer of Xanthine Derivatives (Caffeine, e...

Aarti Pharmalabs is generic APIs & Intermediates manufacturing company & small molecule drug substance CDMO and the largest Indian manufacturer of Xanthine Derivatives (Caffeine, etc.). It has dedicated facilities to manufacture HPAPIs, corticosteroids, cytotoxic & oncology products. It has 3 R&D centers and 3 cGMP plants successfully audited by the USFDA, EUGMP, EDQM, KFDA & COFEPRIS. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Aarti Industries Company Banner

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Ifosfamide

About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...

Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Shanghai Minbiotech CB

05

Vietnam Medi-Pharm Expo
Not Confirmed
arrow
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Ifosfamide

About the Company : Alfa Chemistry offers an extensive catalog of building blocks, reagents, catalysts, reference materials, and research chemicals in a wide range of applications. We also provide ana...

Alfa Chemistry offers an extensive catalog of building blocks, reagents, catalysts, reference materials, and research chemicals in a wide range of applications. We also provide analytical services and laboratory services to our customers. Products listed on our website are either in stock or can be resynthesized within a reasonable time frame.
blank

06

Biotechnica DWC

Algeria
Vietnam Medi-Pharm Expo
Not Confirmed
arrow

Biotechnica DWC

Algeria
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Ifosfamide

About the Company : BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies al...

BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies all over the world. Biotechnica is an integrated global solution provider from design to implementation of industrial projects in the areas of Pharmaceuticals,Agri-food ,Cosmetics and Nutrition. With more than 25 years of experience in the assembly of plants, particularly in the pharmaceutical sector, we accompany our customers in the various stages of their projects – E-CTD Dossieers – Raw Materiels – Equipements – Accessories – Packaging – Distribution.
blank

07

Vietnam Medi-Pharm Expo
Not Confirmed
arrow
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Ifosfamide

About the Company : Founded in 1986, Kekule has developed from a manufacturer of few molecules to a preferred vendor for many complex molecules requiring multistage synthesis. Working with customers a...

Founded in 1986, Kekule has developed from a manufacturer of few molecules to a preferred vendor for many complex molecules requiring multistage synthesis. Working with customers across the world, Kekule has always leveraged its strengths in basic chemistry as well as chemical engineering to deliver high quality APIs and Intermediates in time and at competitive prices. Our value based approach to business has been a foundation for a mutually beneficial long term relationship with our customers. Our employees, technology and infrastructure match the highest international standards.
blank

08

Vietnam Medi-Pharm Expo
Not Confirmed
arrow
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Ifosfamide

About the Company : Polfa Tarchomin located in Warsaw is pharmaceutical company with long tradition and experience in manufacturing and sales of pharmaceutical products. Our core business is related w...

Polfa Tarchomin located in Warsaw is pharmaceutical company with long tradition and experience in manufacturing and sales of pharmaceutical products. Our core business is related with: anti-infectives, CNS medicines, dermatology drugs and human insulin preparations. In general we are in position to produce: tablets and coated tablets; hard gelatinous capsules; dry bottled syrups; sterile powders for injections in glass vials and liquids in glass ampoules; insulin cartridges; dermatological: aerosols, solutions, gels. Polfa Tarchomin will be in position to produce high-potency injectables (vials and prefilled syringes) in 2025.
blank

09

Vietnam Medi-Pharm Expo
Not Confirmed
arrow
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Ifosfamide

About the Company : Huiyu Pharma, established in Oct. 2010, is a specialized pharmaceutical company focusing on developing and manufacturing high-quality oncology products. At present, products in our...

Huiyu Pharma, established in Oct. 2010, is a specialized pharmaceutical company focusing on developing and manufacturing high-quality oncology products. At present, products in our list include the following:Azacitidine, Bendamustine HCl, Bortezomib, Camptothecin, Carboplatin, Decitabine, Docetaxel, Doxorubicin HCl, Epirubicin HCl, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Methotrexate, Oxaliplatin, Paclitaxel, Pemetrexed disodium...We welcome those traders, distributors, and wholesalers who are interested in our products.
blank

10

Synthland

China
Vietnam Medi-Pharm Expo
Not Confirmed
arrow

Synthland

China
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Ifosfamide

About the Company : Synthland is an integrated pharmaceutical company that develops, produce and supplies Active Pharmaceutical Ingredients (APIs) and Intermediates. We also represent some well-known...

Synthland is an integrated pharmaceutical company that develops, produce and supplies Active Pharmaceutical Ingredients (APIs) and Intermediates. We also represent some well-known GMP factories in China for their sales and business development to global market. Most of the products have USDMF, EDMF, CEP, etc, and we have a professional regulatory affairs team who will provide you the documentation as per relative authority's requirement and accelerate your drug application process. Our product category includes Oncology, Anti-infective, Anti-diabetic, Prostaglandin, Immunosuppressant and Veterinary, etc.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Ifoxa (ifosfamide) is a cytotoxic drug that binds to DNA and inhibit DNA synthesis. Ifoxa is indicated for the treatment of malignant diseases.


Lead Product(s): Ifosfamide,Inapplicable

Therapeutic Area: Oncology Brand Name: Ifoxa

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 30, 2024

NanoAlvand

01

NanoAlvand

Iran
arrow

Lead Product(s) : Ifosfamide,Inapplicable

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Ifoxa (ifosfamide) is a cytotoxic drug that binds to DNA and inhibit DNA synthesis. Ifoxa is indicated for the treatment of malignant diseases.

Product Name : Ifoxa

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

November 30, 2024

NanoAlvand
  • Development Update

Details:

Eflornithine is a Amino Acid drug, which is currently being evaluated in Phase II clinical studies for the treatment of Osteosarcoma.


Lead Product(s): Eflornithine Hydrochloride,Topotecan Hydrochloride,Cyclophosphamide,Vincristine Sulfate,Doxorubicin Hydrochloride,Ifosfamide,Etoposide,Cisplatin,

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Amino Acid

Sponsor: US WorldMeds

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 07, 2026

blank

02

Hershey Medical Center

Country
arrow
RDD
Not Confirmed

Hershey Medical Center

Country
arrow
RDD
Not Confirmed

Details : Eflornithine is a Amino Acid drug, which is currently being evaluated in Phase II clinical studies for the treatment of Osteosarcoma.

Product Name : Undisclosed

Product Type : Amino Acid

Upfront Cash : Inapplicable

January 07, 2026

blank
  • Development Update

Details:

Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Lymphoma, B-Cell.


Lead Product(s): Cyclophosphamide,Vincristine Sulfate,Cytarabine,Doxorubincin,Prednisone,Ifosfamide,Etoposide,Methotrexate,Vindelsine

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase II/ Phase IIIProduct Type: Cytotoxic Drug

Sponsor: Shanghai Children's Medical Center | Nanjing Children's Hospital | Children's Hospital of Soochow University | West China Second University Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Institute and Hospital | Xiangy

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 11, 2025

blank

03

Children's Cancer Group, China

Country
arrow
RDD
Not Confirmed

Children's Cancer Group, China

Country
arrow
RDD
Not Confirmed

Lead Product(s) : Cyclophosphamide, Vincristine Sulfate, Cytarabine, Prednisone, Ifosfamide

Therapeutic Area : Oncology

Highest Development Status : Phase II/ Phase III

Partner/Sponsor/Collaborator : Shanghai Children's Medical Center | Nanjing Children's Hospital | Children's Hospital of Soochow University | West China Second University Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Institute and Hospital | Xiangy

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Lymphoma, B-Cell.

Product Name : Undisclosed

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

September 11, 2025

blank

Details:

JS203 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma, B-Cell.


Lead Product(s): JS203,Gemcitabine,Oxaliplatin,Ifosfamide,Carboplatin,Etoposide,Rituximab,Cyclophosphamide,Doxorubicin Hydrochloride,

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Undisclosed

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 23, 2025

blank

04

RDD
Not Confirmed
RDD
Not Confirmed

Details : JS203 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma, B-Cell.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

July 23, 2025

blank
  • Development Update

Details:

Bone Marrow Aspiration is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Sarcoma.


Lead Product(s): Bone Marrow Aspiration,Cyclophosphamide,Doxorubicin Hydrochloride,Etoposide,18-F Fludeoxyglucose,Ifosfamide,Irinotecan Hydrochloride,Magnetic Resonance Imaging,Radiation,Regorafenib,Procedure,Vincristine Sulfate

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase II/ Phase IIIProduct Type: Undisclosed

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 11, 2025

blank

05

Children's Oncology Group

Country
arrow
RDD
Not Confirmed

Children's Oncology Group

Country
arrow
RDD
Not Confirmed

Details : Bone Marrow Aspiration is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Sarcoma.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

February 11, 2025

blank
  • Development Update

Details:

Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pleuropulmonary Blastoma.


Lead Product(s): Cyclophosphamide,Dactinomycin,Vincristine Sulfate,Dexrazoxane,Doxorubicin Hydrochloride,Ifosfamide,Magnetic Resonance Imaging,Topotecan Hydrochloride

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Cytotoxic Drug

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 18, 2024

blank

06

Children's Oncology Group

Country
arrow
RDD
Not Confirmed

Children's Oncology Group

Country
arrow
RDD
Not Confirmed

Details : Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pleuropulmonary Blastoma.

Product Name : Undisclosed

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

October 18, 2024

blank
  • Development Update

Details:

Masct-I is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leiomyosarcoma.


Lead Product(s): Masct-I,Doxorubicin Hydrochloride,Ifosfamide

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibody, Unconjugated

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 26, 2024

blank

07

HRYZ Biotech

Country
arrow
RDD
Not Confirmed

HRYZ Biotech

Country
arrow
RDD
Not Confirmed

Details : Masct-I is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leiomyosarcoma.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

February 26, 2024

blank

Details:

ADI PEG20 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sarcoma.


Lead Product(s): Pegargiminase,Ifosfamide,Mesna

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Enzyme

Sponsor: Polaris Group

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 14, 2023

blank

08

RDD
Not Confirmed
RDD
Not Confirmed

Details : ADI PEG20 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sarcoma.

Product Name : Undisclosed

Product Type : Enzyme

Upfront Cash : Inapplicable

April 14, 2023

blank
  • Development Update

Details:

Prednisone is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.


Lead Product(s): Prednisone,Vincristine Sulfate,Pegylated-Asparaginase,Bortezomib,Cytarabine,Cyclophosphamide,Daunorubicin,Mercaptopurine,Methotrexate,

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Steroid

Sponsor: Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 12, 2023

blank

09

Children's Cancer Group, China

Country
arrow
RDD
Not Confirmed

Children's Cancer Group, China

Country
arrow
RDD
Not Confirmed

Lead Product(s) : Prednisone, Vincristine Sulfate, Bortezomib, Cytarabine, Cyclophosphamide

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Shanghai Children's Medical Center | Beijing Children's Hospital | Children's Hospital of Scow University | West China Second University Hospital | Nanjing Children's Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Inst

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Prednisone is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.

Product Name : Undisclosed

Product Type : Steroid

Upfront Cash : Inapplicable

January 12, 2023

blank

Details:

Obinutuzumab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, B-Cell.


Lead Product(s): Obinutuzumab,Glofitamab,Rituximab,Ifosfamide,Carboplatin,Etoposide,Tocilizumab

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 09, 2022

blank

10

F. Hoffmann-La Roche

Switzerland
arrow
RDD
Not Confirmed

F. Hoffmann-La Roche

Switzerland
arrow
RDD
Not Confirmed

Details : Obinutuzumab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, B-Cell.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

September 09, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFEX

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/VIAL

Packaging :

Approval Date : 1988-12-30

Application Number : 19763

Regulatory Info : RX

Registration Country : USA

blank

02

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFEX

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 3GM/VIAL

Packaging :

Approval Date : 1988-12-30

Application Number : 19763

Regulatory Info : RX

Registration Country : USA

blank

03

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE; MESNA

Brand Name : IFEX/MESNEX KIT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/VIAL;100MG/ML

Packaging :

Approval Date : 1992-10-10

Application Number : 19763

Regulatory Info : DISCN

Registration Country : USA

blank

04

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE; MESNA

Brand Name : IFEX/MESNEX KIT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 3GM/VIAL;100MG/ML

Packaging :

Approval Date : 1992-10-10

Application Number : 19763

Regulatory Info : DISCN

Registration Country : USA

blank

05

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/VIAL

Packaging :

Approval Date : 2002-05-28

Application Number : 76078

Regulatory Info : RX

Registration Country : USA

blank

06

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 3GM/VIAL

Packaging :

Approval Date : 2002-05-28

Application Number : 76078

Regulatory Info : RX

Registration Country : USA

blank

07

Hikma Pharmaceuticals

United Kingdom
RDD
Not Confirmed
arrow

Hikma Pharmaceuticals

United Kingdom
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/20ML (50MG/ML)

Packaging :

Approval Date : 2011-06-29

Application Number : 76619

Regulatory Info : RX

Registration Country : USA

blank

08

Hikma Pharmaceuticals

United Kingdom
RDD
Not Confirmed
arrow

Hikma Pharmaceuticals

United Kingdom
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 3GM/60ML (50MG/ML)

Packaging :

Approval Date : 2011-06-29

Application Number : 76619

Regulatory Info : RX

Registration Country : USA

blank

09

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/20ML (50MG/ML)

Packaging :

Approval Date : 2007-04-04

Application Number : 76657

Regulatory Info : RX

Registration Country : USA

blank

10

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE; MESNA

Brand Name : IFOSFAMIDE/MESNA KIT

Dosage Form : INJECTABLE;INTRAVENOUS

Dosage Strength : 1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)

Packaging :

Approval Date : 2002-02-26

Application Number : 75874

Regulatory Info : DISCN

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFEX

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/VIAL

Approval Date : 1988-12-30

Application Number : 19763

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AP

blank

02

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFEX

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 3GM/VIAL

Approval Date : 1988-12-30

Application Number : 19763

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AP

blank

03

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE; MESNA

Brand Name : IFEX/MESNEX KIT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/VIAL;100MG/ML

Approval Date : 1992-10-10

Application Number : 19763

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

04

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE; MESNA

Brand Name : IFEX/MESNEX KIT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 3GM/VIAL;100MG/ML

Approval Date : 1992-10-10

Application Number : 19763

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

05

EXTROVIS

Switzerland
RDD
Not Confirmed
arrow

EXTROVIS

Switzerland
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/20ML (50MG/ML)

Approval Date : 2012-11-26

Application Number : 201689

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

06

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/20ML (50MG/ML)

Approval Date : 2009-09-22

Application Number : 90181

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

07

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 3GM/60ML (50MG/ML)

Approval Date : 2009-09-22

Application Number : 90181

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

08

HIKMA

United Kingdom
RDD
Not Confirmed
arrow

HIKMA

United Kingdom
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/20ML (50MG/ML)

Approval Date : 2011-06-29

Application Number : 76619

RX/OTC/DISCN : RX

RLD : No

TE Code : AP

blank

09

HIKMA

United Kingdom
RDD
Not Confirmed
arrow

HIKMA

United Kingdom
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 3GM/60ML (50MG/ML)

Approval Date : 2011-06-29

Application Number : 76619

RX/OTC/DISCN : RX

RLD : No

TE Code : AP

blank

10

MEITHEAL

U.S.A
RDD
Not Confirmed
arrow

MEITHEAL

U.S.A
arrow
RDD
Not Confirmed

IFOSFAMIDE

Brand Name : IFOSFAMIDE

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 1GM/20ML (50MG/ML)

Approval Date : 2007-04-04

Application Number : 76657

RX/OTC/DISCN : RX

RLD : No

TE Code : AP

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form : Injection/Infusion Solution

Dosage Strength : 2000mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

02

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form : Powder For Solution For Injection

Dosage Strength : 1g

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

03

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form : Powder For Solution For Injection

Dosage Strength : 500mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

04

Baxter A/S

U.S.A
RDD
Not Confirmed
arrow

Baxter A/S

U.S.A
arrow
RDD
Not Confirmed

Ifosphamide

Brand Name : Holoxan

Dosage Form : Injection/Infusion Solution

Dosage Strength : 1g

Packaging :

Approval Date : 28-11-1984

Application Number : 28101091881

Regulatory Info : Prescription

Registration Country : Denmark

blank

05

Baxter A/S

U.S.A
RDD
Not Confirmed
arrow

Baxter A/S

U.S.A
arrow
RDD
Not Confirmed

Ifosphamide

Brand Name : Holoxan

Dosage Form : Injection/Infusion Solution

Dosage Strength : 500mg

Packaging :

Approval Date : 28-11-1984

Application Number : 28101091781

Regulatory Info : Prescription

Registration Country : Denmark

blank

06

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form : Injection/Infusion Solution

Dosage Strength : 500mg

Packaging :

Approval Date : 08-02-1990

Application Number : 2.03E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

07

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form : Injection/Infusion Solution

Dosage Strength : 2000mg

Packaging :

Approval Date : 08-02-1990

Application Number : 2.03E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

08

Baxter Ag

Germany
RDD
Not Confirmed
arrow

Baxter Ag

Germany
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form : Powder For Infusion

Dosage Strength : 500mg

Packaging :

Approval Date : 11/09/1979

Application Number : 41217

Regulatory Info : Allowed

Registration Country : Switzerland

blank

09

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Mitoxana

Dosage Form : Powder For Concentrate For Injectable Solution And For Infusion

Dosage Strength : 2G

Packaging :

Approval Date : 2007-03-02

Application Number :

Regulatory Info : Authorised

Registration Country : Malta

blank

10

Orifarm Ab

Denmark
RDD
Not Confirmed
arrow

Orifarm Ab

Denmark
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form : Injection/Infusion Solution

Dosage Strength :

Packaging :

Approval Date : 12-07-2007

Application Number : 2.01E+13

Regulatory Info : Deregistered

Registration Country : Sweden

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Australia

read-more
read-more

01

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

02

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

03

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

04

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : Holoxan

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name :

Dosage Form : INJECTION

Dosage Strength : 1000MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : India

blank

01

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Dosage : INJECTION

Dosage Strength : 1000MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

02

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name :

Dosage Form : INJECTION

Dosage Strength : 2000MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : India

blank

02

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Dosage : INJECTION

Dosage Strength : 2000MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

03

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : FOSFA

Dosage Form : Injection

Dosage Strength : 1G

Packaging : 1 Vial

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

03

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Dosage : Injection

Dosage Strength : 1G

Brand Name : FOSFA

Approval Date :

Application Number :

Registration Country : India

blank

04

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : FOSFA

Dosage Form : Injection

Dosage Strength : 2G

Packaging : 1 Vial

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

04

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Dosage : Injection

Dosage Strength : 2G

Brand Name : FOSFA

Approval Date :

Application Number :

Registration Country : India

blank

05

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name : FOSFA

Dosage Form : Injection

Dosage Strength : 3G

Packaging : 1 Vial

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

05

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Dosage : Injection

Dosage Strength : 3G

Brand Name : FOSFA

Approval Date :

Application Number :

Registration Country : India

blank

06

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name :

Dosage Form : Vial

Dosage Strength : 2G

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

06

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Dosage : Vial

Dosage Strength : 2G

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

07

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name :

Dosage Form : Injection

Dosage Strength : 0.5G

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : China

blank

07

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Dosage : Injection

Dosage Strength : 0.5G

Brand Name :

Approval Date :

Application Number :

Registration Country : China

blank

08

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name :

Dosage Form : Injection

Dosage Strength : 1G

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : China

blank

08

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Dosage : Injection

Dosage Strength : 1G

Brand Name :

Approval Date :

Application Number :

Registration Country : China

blank

09

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Brand Name :

Dosage Form : Injection

Dosage Strength : 40MG/ML

Packaging : 10 ml + WFI

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

09

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide

Dosage : Injection

Dosage Strength : 40MG/ML

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank

10

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide; Mesna

Brand Name : SOLOXAN-RD

Dosage Form : Injection

Dosage Strength : 1gm; 3amps (200mg/2ml)

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

10

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Ifosfamide; Mesna

Dosage : Injection

Dosage Strength : 1gm; 3amps (200mg/2ml)

Brand Name : SOLOXAN-RD

Approval Date :

Application Number :

Registration Country : India

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - INJECTABLE;INJECTION - 1GM/VIAL

USFDA APPLICATION NUMBER - 19763

read-more

DOSAGE - INJECTABLE;INJECTION - 3GM/VIAL

USFDA APPLICATION NUMBER - 19763

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

read-more
read-more

Topical

read-more
read-more

API Stability Enhancers

read-more
read-more

Solubilizers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 3778-73-2 / Ifosfamide API manufacturers, exporters & distributors?

Ifosfamide manufacturers, exporters & distributors 1

90

PharmaCompass offers a list of Ifosfamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ifosfamide manufacturer or Ifosfamide supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ifosfamide manufacturer or Ifosfamide supplier.

API | Excipient name

Ifosfamide

Synonyms

Isophosphamide, 3778-73-2, Iphosphamide, Isofosfamide, Ifex, Ifosfamid

Cas Number

3778-73-2

Unique Ingredient Identifier (UNII)

UM20QQM95Y

About Ifosfamide

Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.

Ifex Manufacturers

A Ifex manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ifex, including repackagers and relabelers. The FDA regulates Ifex manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ifex API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Ifex manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Ifex Suppliers

A Ifex supplier is an individual or a company that provides Ifex active pharmaceutical ingredient (API) or Ifex finished formulations upon request. The Ifex suppliers may include Ifex API manufacturers, exporters, distributors and traders.

click here to find a list of Ifex suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Ifex USDMF

A Ifex DMF (Drug Master File) is a document detailing the whole manufacturing process of Ifex active pharmaceutical ingredient (API) in detail. Different forms of Ifex DMFs exist exist since differing nations have different regulations, such as Ifex USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Ifex DMF submitted to regulatory agencies in the US is known as a USDMF. Ifex USDMF includes data on Ifex's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ifex USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Ifex suppliers with USDMF on PharmaCompass.

Ifex CEP

A Ifex CEP of the European Pharmacopoeia monograph is often referred to as a Ifex Certificate of Suitability (COS). The purpose of a Ifex CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ifex EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ifex to their clients by showing that a Ifex CEP has been issued for it. The manufacturer submits a Ifex CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ifex CEP holder for the record. Additionally, the data presented in the Ifex CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ifex DMF.

A Ifex CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ifex CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Ifex suppliers with CEP (COS) on PharmaCompass.

Ifex WC

A Ifex written confirmation (Ifex WC) is an official document issued by a regulatory agency to a Ifex manufacturer, verifying that the manufacturing facility of a Ifex active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ifex APIs or Ifex finished pharmaceutical products to another nation, regulatory agencies frequently require a Ifex WC (written confirmation) as part of the regulatory process.

click here to find a list of Ifex suppliers with Written Confirmation (WC) on PharmaCompass.

Ifex NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ifex as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Ifex API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Ifex as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Ifex and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ifex NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Ifex suppliers with NDC on PharmaCompass.

Ifex GMP

Ifex Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Ifex GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ifex GMP manufacturer or Ifex GMP API supplier for your needs.

Ifex CoA

A Ifex CoA (Certificate of Analysis) is a formal document that attests to Ifex's compliance with Ifex specifications and serves as a tool for batch-level quality control.

Ifex CoA mostly includes findings from lab analyses of a specific batch. For each Ifex CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Ifex may be tested according to a variety of international standards, such as European Pharmacopoeia (Ifex EP), Ifex JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ifex USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty